AstraZeneca said it will spend $50 billion to enlarge its U.S. manufacturing and research footprint by 2030, its biggest single-country commitment to date. The Anglo-Swedish drugmaker will pour about $4 billion into a new active-ingredient plant in Virginia that will supply experimental weight-loss and metabolic medicines, and will expand R&D or cell-therapy sites in Maryland, Massachusetts, California, Indiana and Texas. The program builds on a $3.5 billion pledge made last year and could create tens of thousands of jobs, the company said. Chief Executive Officer Pascal Soriot unveiled the plan in Washington alongside Virginia Governor Glenn Youngkin, calling it a cornerstone of AstraZeneca’s goal to lift annual revenue to $80 billion by the end of the decade, with half generated in the United States. AstraZeneca joins rivals such as Roche, Johnson & Johnson and Eli Lilly that have collectively committed more than $300 billion to U.S. expansion this year. The rush to onshore production follows President Donald Trump’s threat to impose tariffs of as much as 200 percent on imported pharmaceuticals. Commerce Secretary Howard Lutnick is leading an inquiry that could pave the way for the levies. While Soriot said the investment would have proceeded regardless, he acknowledged that the policy backdrop is accelerating decisions to localize drug supply chains.